-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, GzBxSnRi1Jlr7qnhzaPhxtNKrGkNGUd3Y4yBnWOkQyCyDTHlXkp/gHrvNzqOpTMe OMLWTg7ja5CnVqi44d8TQA== 0000898430-02-003031.txt : 20020813 0000898430-02-003031.hdr.sgml : 20020813 20020813162316 ACCESSION NUMBER: 0000898430-02-003031 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20020813 ITEM INFORMATION: FILED AS OF DATE: 20020813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-12477 FILM NUMBER: 02730007 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 BUSINESS PHONE: 805-447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE STREET 2: MAIL STOP 27-3-C CITY: THOUSAND OAKS STATE: CA ZIP: 91320-1799 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 8-K 1 d8k.htm FORM 8-K Prepared by R.R. Donnelley Financial -- Form 8-K
 
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 13, 2002
 
Amgen Inc.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
     
000-12477
     
95-3540776
(State or Other Jurisdiction
of Incorporation)
     
(Commission
File Number)
     
(I.R.S. Employer
Identification No.)
 
One Amgen Center Drive
Thousand Oaks, California 91320-1799
(Address of Principal Executive Offices)
 
 
(805) 447-1000
(Registrant’s telephone number, including area code)
 
 
 

 
ITEM 9.    REGULATION FD DISCLOSURE
 
On August 13, 2002, Amgen Inc. (the “Registrant”) filed its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2002 (the “Form 10-Q”) with the Securities and Exchange Commission. The Registrant’s Form 10-Q was accompanied by the certifications required by 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, and the text of such certifications is set forth below:
 
“Certification of Chief Executive Officer
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
 
 
(i)
 
the accompanying Quarterly Report on Form 10-Q of the Company for the three months ended June 30, 2002 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
 
(ii)
 
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
   
Dated: August 13, 2002
          
/s/    Kevin W. Sharer
               
Kevin W. Sharer
               
Chairman of the Board, Chief Executive Officer
               
and President
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.”

2

 
“Certification of Chief Financial Officer
 
Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Amgen Inc. (the “Company”) hereby certifies that:
 
 
(i)
 
the accompanying Quarterly Report on Form 10-Q of the Company for the three months ended June 30, 2002 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
 
 
(ii)
 
information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Dated:    August 13, 2002
        
               
/s/    RICHARD D. NANULA
               
Richard D. Nanula
Executive Vice President, Finance, Strategy and Communications, and Chief Financial Officer
 
The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.”
 

3

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: August 13, 2002
      
AMGEN INC.
           
By:
  
/s/    Richard D. Nanula        
               
Richard D. Nanula
Executive Vice President, Finance, Strategy and Communications, and Chief Financial Officer

4
-----END PRIVACY-ENHANCED MESSAGE-----